leisure time -WSS

leisure time

author：Wikipedia 2025-09-06 03:55:37 - browse：4

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Evacuations in place as 3 wildfires burn in eastern Washington state

WSS

Woman returns to dialysis after doctors remove transplanted pig kidney

Innovation in antibiotics is ailing. 'Brain drain' may kill it

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Hilary expected to bring catastrophic, life

How to increase colonoscopy rates? Looks like an AI can help

Majority of Americans think Trump's Ga. election interference case is serious: POLL

explore

leisure time

leisure time

At least 13 dead in Texas as scorching temps continue

Ultragenyx gene therapy for rare liver ailment succeeds in late

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA's Pazdur wants cancer trials to range beyond China alone

Drug repurposing or repositioning? The language matters

How to increase colonoscopy rates? Looks like an AI can help

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Let's speed up science by embracing open access publishing

How one medical school became remarkably diverse

ActiGraph execs on goal of drug approvals with digital endpoints

explore

Change Healthcare can notify patients about the breach, HHS says

Letters to First Opinion on caregivers, digital health, and more

Change Healthcare can notify patients about the breach, HHS says

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

An interview with Robert F. Kennedy Jr. on vaccines

focus

focus

Wikipedia

focus